8 completed, 7 active not recruiting, 4 terminated, 2 unknown. 9 Phase 3, 7 Phase 2, 5 Phase 1, 1 Early Phase 1, 1 Not applicable.
Follow Fallopian Tube Transitional Cell Carcinoma: new trials by email Literature Review of Fallopian Tube Transitional Cell Carcinoma trials Research Report on Fallopian Tube Transitional Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial Chemotherapy, Laparotomy, Minimally Invasive Surgery - Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Recruiting | M.D. Anderson Cancer Center | 580 | 2020-08-05 | 2026-09-14 |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Biospecimen Collection, Computed Tomography, Echocardiography Test - Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 55 | 2020-05-07 | 2026-07-20 |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors Exercise Counseling, Aerobic Exercise, Physiological Support - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Not applicable | Terminated | University of Washington | 64 | 2018-12-05 | 2023-11-29 |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2017-05-05 | 2024-03-13 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer Cediranib, Cediranib Maleate, Computed Tomography - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 582 | 2016-05-03 | 2026-10-01 |
| Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Biospecimen Collection, Carboplatin, Cediranib Maleate - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 579 | 2016-03-28 | 2026-10-01 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 17 | 2015-03-13 | 2025-12-11 |
| MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 34 | 2014-04-25 | 2026-08-24 |
| Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor | Early Phase 1 | Completed | Mayo Clinic | 19 | 2014-04-14 | 2025-10-31 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Behavioral Dietary Intervention, Compliance Monitoring, Counseling - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | Gynecologic Oncology Group | 1070 | 2012-06-18 | 2018-02-19 |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Elesclomol Sodium, Paclitaxel - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | GOG Foundation | 58 | 2010-12-13 | 2021-10-20 |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 692 | 2010-09-27 | 2026-05-29 |
| First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Bevacizumab, Carboplatin, Paclitaxel - Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 33 | 2010-04-14 | 2022-10-28 |
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bortezomib, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 33 | 2010-04-05 | 2019-08-09 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 431 | 2009-10-28 | 2021-10-20 |
| Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1560 | 2009-08-11 | 2026-06-02 |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Docetaxel - Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1052 | 2007-12-06 | 2025-12-30 |
| YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Terminated | Gynecologic Oncology Group | 2500 | 2007-09-01 | 2018-05-22 |
Showing 20 of 22. Sign in to see all of them.
Fallopian Tube Neoplasms (18) · Ovarian Neoplasms (16) · Brenner Tumor (14) · Adenocarcinoma, Mucinous (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenocarcinoma, Clear Cell (1) · Adrenocortical Carcinoma (1) · Bile Duct Neoplasms (1) · Carcinoma (1) · Carcinoma, Acinar Cell (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Basal Cell (1) · Carcinoma, Endometrioid (1) · Carcinoma, Giant Cell (1) · Carcinoma, Transitional Cell (1)
Adnexal Diseases (21) · Endocrine System Diseases (21) · Female Urogenital Diseases (21) · Female Urogenital Diseases and Pregnancy Complications (21) · Genital Diseases (21) · Genital Diseases, Female (21) · Genital Neoplasms, Female (21) · Gonadal Disorders (21) · Ovarian Diseases (21) · Urogenital Diseases (21) · Urogenital Neoplasms (21) · Neoplasms (20) · Neoplasms by Site (20) · Fallopian Tube Diseases (18) · Endocrine Gland Neoplasms (17)
Taxes (13) · Paclitaxel (12) · Bevacizumab (9) · Disulfides (9) · Immunoglobulin G (9) · Carboplatin (8) · Magnetic Resonance Spectroscopy (5) · Doxorubicin (4) · Specimen Handling (4) · liposomal doxorubicin (4) · Gemcitabine (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Cisplatin (2) · Platinum (2) · Topotecan (2)
National Cancer Institute (NCI) (10) · Mayo Clinic (4) · M.D. Anderson Cancer Center (3) · GOG Foundation (2) · Gynecologic Oncology Group (2) · University of Washington (1)
United States (22) · Canada (5) · South Korea (5) · Japan (4) · Guam (1) · Italy (1) · Mexico (1) · Netherlands (1) · Puerto Rico (1)
Matthew S. Block, M.D., Ph.D. (2) · Anil K. Sood, MD (1) · Anil Sood (1) · Bradley J Monk (1) · David Alberts (1) · Don Dizon (1) · Evanthia Galanis, M.D. (1) · Evanthia Galanis, MD (1) · Joan L Walker (1) · John K Chan (1) · Jose A Rauh-Hain (1) · Joyce F Liu (1) · Jung-min Lee (1) · Katherine Bell-McGuinn (1) · Katherine M Bell-McGuinn (1)
PMID 37185961, PMID 21941283, PMID 22204724, PMID 23219660, PMID 26487588, PMID 26933849, PMID 27394382, PMID 28341300, PMID 28438473, PMID 29550184, PMID 30309721, PMID 31002578, PMID 31216226, PMID 31708167, PMID 31722153, PMID 31969335, PMID 33362722, PMID 33610319, PMID 33882143, PMID 34380663, PMID 34716198, PMID 35144591, PMID 35170751, PMID 35290101, PMID 35759733, PMID 36252167, PMID 36608382, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39361946, PMID 39417692, PMID 39570589, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
U10CA180868 (11), U10CA027469 (9), P50CA136393 (2), R01CA136547 (1), R01CA200507 (1), R21CA215662 (1), U10CA101165 (1), U10CA180830 (1), U10CA180888 (1), UG1CA189867 (1), UM1CA186691 (1)